Replies to post #39364 on OncoSec Medical Inc (ONCSQ)

[twiz0019]

Excellent find hschlauch and very relevant. They only reported a 17% PARTIAL response....no indication of any complete response, so there must not have been any. These results are below what ONCS reported in the combo trial for the 9 patients who had previously failed Keyyruda

[Titan V]

I was looking at this yesterday. Among their 7 anti-PD-1 naive patients that showed a 100% ORR, one cannot tell for sure if they responded as such due to the combo treatment or due to Keytruda alone, the same question that was raised for ONCS's responders in the IST. At least with ONCS, we had some measure that the patients were predicted non-responders to Keytruda alone.

As for the anti-PD1 refractory patients, the response rates are less than ONCS's - not a single complete response and a lower partial response rate of 17% compared to the 22% (2 out of 9 pts) of ONCS.

Still not conclusive as to which one is the better therapy due to the small samples, but the upcoming registration trial should provide a better picture.

[Titan V]

Hschlauch, any thoughts on Merck's melanoma combos with Incyte (IDO-1) and Amgen (T-Vec)? I think results from these trials will be important to watch as well. MRK listed these combos in their ASCO presentation.
http://s21.q4cdn.com/488056881/files/doc_presentations/2017/june/ASCO-2017-Investor-Resource-FINAL.pdf (slide 7)
(ONCS reg. trial was not listed IMO because MRK is running the aforementioned registration combos, unlike ONCS's where ONCS is running it and just getting Keytruda from MRK.)

On a separate note, a few days ago INCY shared keytruda lung cancer combo data and the reaction was lukewarm, mainly because INCY withheld some data.
https://www.thestreet.com/story/14161896/1/missing-patients-cloud-view-of-incyte-s-ido-drug-lung-cancer-study.html

It would be something if the upcoming reg. trial shows better response rates than MRK + INCY. Safety data towards the end of the trial would also be interesting to watch. So far, ONCS trials have had a spotless safety record.